Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial

被引：1

作者：

Stintzing, Sebastian

Tabernero, Josep

Satoh, Taroh

Dasari, Arvind

Lonardi, Sara

Eng, Cathy

Garcia-Carbonero, Rocio

Elez, Elena

Yoshino, Takayuki

Sobrero, Alberto F.

Yao, James C.

Kasper, Stefan

Arnold, Dirk

Basic, Edin

Granold, Matthias

Petschulies, Marco

Wu, Liwen

Chen, Lucy

Yang, Zhao

Van Cutsem, Eric

机构：

[1] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany

[2] Vall dHebron Hosp Campus, Vall dHebron Inst Oncol, Barcelona, Spain

[3] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Japan

[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[5] Veneto Inst Oncol IOV IRCCS, Med Oncol Unit 1, Padua, Italy

[6] Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA

[7] Hosp Univ 12 Octubre Imas12, UCM, Madrid, Spain

[8] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[9] Azienda Osped San Martino, Dept Med Oncol, Genoa, Italy

[10] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[11] AK Altona, Dept Oncol & Hematol, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[12] Takeda Pharm Vertrieb GmbH & Co KG, Berlin, Germany

[13] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[14] HUTCHMED Int Inc, Florham Pk, NJ USA

[15] Univ Hosp Gasthuisberg Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

[16] KULeuven, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

130-231; 261-492-3532-2370-7650-2700; 283-237-255; 261-492-3532-2370-12160; 281-5277-2560; 9; 3; 2; 2461; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：116 / 116

页数：1

共 50 条

[1] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
Stintzing, Sebastian
Tabernero, Josep
Satoh, Taroh
Dasari, Arvind
Lonardi, Sara
Eng, Cathy
Garcia-Carbonero, Rocio
Elez, Elena
Yoshino, Takayuki
Sobrero, Alberto F.
Yao, James C.
Kasper, Stefan
Arnold, Dirk
Basic, Edin
Granold, Matthias
Petschulies, Marco
Wu, Liwen
Chen, Lucy F.
Yang, Zhao
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2
Stintzing, S.
Tabernero, J.
Satoh, T.
Dasari, A.
Lonardi, S.
Eng, C.
Garcia-Carbonero, R.
Elez, E.
Yoshino, T.
Sobrero, A. F.
Yao, J. C.
Kasper, S.
Arnold, D.
Basic, E.
Granold, M.
Petschulies, M.
Wu, L.
Chung, Y. -C
Chen, L.
Yang, Z.
Van Cutsem, E.
ESMO OPEN, 2025, 10 (03)
[3] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
Bai, Yu-Xian
Qin, Shukui
Li, Jin
Deng, Yanhong
Yang, Lei
Xu, Rui-hua
Zhong, Haijun
Chen, Zhendong
Pan, Hongming
Guo, Weijian
Shu, Yongqian
Peng, Cike
Chen, Yun
Li, Hongyan
Wang, Ning
Guo, Xiaojun
Wang, Wei
Fan, Songhua
Xu, Jian-Ming
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Efficacy and safety of fruquintinib (F) plus best supportive care (BSC) vs placebo (P) plus BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Kotani, D.
Yoshino, T.
Paulson, A. S.
Masuishi, T.
Hochster, H.
Krauss, J.
Sunakawa, Y.
Takashima, A.
Yamazaki, K.
Kawakami, H.
Nishina, T.
Komatsu, Y.
Esaki, T.
Eng, C.
Dasari, N. A.
Yu, Z.
Chen, L.
Yang, T.
Schelman, W.
Satoh, T.
ANNALS OF ONCOLOGY, 2023, 34 : S1506 - S1507
[5] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial.
Li, Jin
Xu, Ruihua
Bai, Yuxian
Xu, Jianming
Liu, Tianshu
Shen, Lin
Wang, Liwei
Pan, Hongming
Han, Rubing
Chen, Yun
Peng, Cike
Fan, Songhua
Hua, Ye
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[6] Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) plus best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2
Lonardi, Sara
Dasari, Arvind
Garcia-Carbonero, Rocio
Yoshino, Takayuki
Garcia-Alfonso, Pilar
Kocsis, Judit
Cremolini, Chiara
Ghiringhelli, Francois
Shergill, Ardaman
Hochster, Howard S.
Ducreux, Michel
Arnold, Dirk
Sundaresan, Varsha
Kasar, Siddha
Pina, Adela
Yu, Ziji
Schelman, William R.
Chen, Lucy
Tabernero, Josep
CANCER RESEARCH, 2024, 84 (06)
[7] Estimated net benefit of avelumab (AVE) plus best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
Powles, Thomas
Cislo, Paul
Kirker, Melissa
Chang, Jane
Gharibian, Norbek
Thompson, Allison
Costa, Nuno
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
J Wang
Z Zhao
B Barber
B Sherrill
M Peeters
J Wiezorek
British Journal of Cancer, 2011, 104 : 1848 - 1853
[9] A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
Wang, J.
Zhao, Z.
Barber, B.
Sherrill, B.
Peeters, M.
Wiezorek, J.
BRITISH JOURNAL OF CANCER, 2011, 104 (12) : 1848 - 1853
[10] A Q-TWIST ANALYSIS COMPARING PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) WITH BSC ALONE IN PATIENTS WITH WILD-TYPE KRAS METASTATIC COLORECTAL CANCER
Wang, J.
Zhao, Z.
Sherrill, B.
Peeters, M.
Wiezorek, J.
Barber, B.
VALUE IN HEALTH, 2011, 14 (03) : A170 - A170

← 1 2 3 4 5 →